The Urinary System Infections caused by Extended- Spectrum-B-Lactamase-producing Escherichia coli and Klebsiella pneumoniae Strains

Production of ?-Lactamase enzymes is an important mechanism of resistance in Gram-negative bacteria. The aim of this study was to investigate the relationship between the Extended-Spectrum ?-Lactamase (ESBL)-positive Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) strains isolated from the urine cultures and the underlying diseases and also to assess the antibiotic resistance. The bacteria were identified according to conventional methods including colony morphology, gram stains, oxidase test and biochemical tests (indole production, Triple Sugar Iron (TSI) agar, Simmon's Citrate agar, Christensen's Urea agar, and motility test medium). BD Phoenix automated system (Becton Dickinson, USA) was used for further identification of the bacteria that were identified as E. coli and K. pneumoniae and for assessing the resistance rates and ESBL production. A total of 401 E. coli and 58 K. pneumoniae strains were isolated from the urinary specimens. Of these, 159 (39.6%) of E. coli and 26 (44.8%) of K. pneumoniae strains were ESBL-positive. The most active antibiotics against ESBL-positive E. coli and K. pneumoniae strains were carbapenems. Underlying diseases were detected in a total of 148 ESBL-positive strains (80%), including 127 (79.8%) of E. coli and 21 (80.8%) of K. pneumoniae strains. Common underlying diseases were benign prostate hyperplasia (BPH), urolithiasis, neurogenic bladder, urethral stricture, vesicoureteral reflux (VUR), hypospadias, ureteropelvic junction (UPJ) obstruction, vesicointestinal fistula, and cystocele (p<0.05). In the treatment of urinary system infections, ESBL-positive E. coli and K. pneumoniae strains should be kept in mind and the underlying diseases should be studied and treated.

___

1. Liu HY, Lin HC, Lin YC, et al. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011; 44: 364-368.

2. Buehlmann M, Bruderer T, Frei R, Widmer AF. Effectiveness of a new decolonisation regimen for eradication of extended-spectrum ?- lactamase-producing Enterobacteriaceae. J Hosp Infect 2011; 77: 113-117.

3. Gholipour A, Soleimani N, Shokri D, Mobasherizadeh S, Kardi M, Baradaran A. Phenotypic and Molecular Characterization of Extended-Spectrum ?-Lactamase Produced by Escherichia coli, and Klebsiella pneumoniae Isolates in an Educational Hospital. Jundishapur J Microbiol 2014; 7: e11758.

4. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.

5. Gündem N, Çıkman A, Gülhan B. Extended spectrum beta-lactamase (ESBL) production and antibiotic resistances of Escherichia coli and Klebsiella spp. strains isolated from urine cultures. J Clin Exp Invest 2013; 4: 56-62.

6. Sorlózano A, Gutiérrez J, Romero JM, et al. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum betalactamase producing Escherichia coli. J Basic Microbiol 2007; 47: 413-416.

7. Wiegand I, Geiss HK, Mack D, Stürenburg E, Seifert H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol 2007; 45: 1167-1174.

8. Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008; 14: 144-153.

9. Kim JY, Sohn JW, Park DW, et al. Control of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 2008; 62: 416-421.

10. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum betalactamases. J Antimicrob Chemother 2006; 57: 780- 783.

11. Rupp ME, Fey PD. Extended spectrum ?-Lactamase (ESBL)-producing Enterobacteriaceae considerations for diagnosis, prevention and drug treatment. Drugs 2003; 63: 353-365.

12. Ipekci T, Seyman D, Berk H, Celik O. Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Infect Chemother 2014; 12: 762-767.

13. Yaşar K, Pehlivanoğlu F, Şengöz G. Effectiveness of Fosfomycin as an Alternative Therapy Choice to ESBL Producing Escherichia coli Strains Isolated from Complicated Urinary Tract Infections. ANKEM Derg 2011; 25: 12-16.

14. Özçakar ZB, Yalçınkaya F, Kavaz A, et al: Urinary tract infections owing to ESBLproducing bacteria: microorganisms change-- clinical pattern does not. Acta Paediatr 2011; 100: e61-64.

15. Kuzucu Ç, Yetkin F, Görgeç S, Ersoy Y. Investigation of the Susceptibilities of ExtendedSpectrum Beta-Lactamase Producing Escherichia coli and Klebsiella spp. Strains to Ertapenem and Other Carbapenems. Mikrobiyol Bul 2011; 45: 28-35.

16. Deveci Ö, Yula E, Tekin A. Frequency of extended spectrum beta-lactamase and resistance to antibiotics in Escherichia coli strains isolated from urinary cultures. J Clin Exp Invest 2010; 1: 182-186.

17. Akyar I. Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital. Mikrobiyol Bul 2008; 42: 713-715.

18. Alhambra A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alós JI. In vitro susceptibility of recent antibioticresistan urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004; 53: 1090- 1094.